Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Abbott, Galapagos Sign Arthritis Pact

by Rick Mullin
March 5, 2012 | A version of this story appeared in Volume 90, Issue 10

Abbott Laboratories and Galapagos are joining to develop GLPG0634, an oral Janus kinase 1 inhibitor in Phase II development at Galapagos for the treatment of autoimmune diseases such as rheumatoid arthritis. Abbott will make an initial payment of $150 million to Galapagos. Upon successful completion of Phase II studies, Abbott will license the program for a one-time fee of $200 million and will take on full responsibility for Phase III trials. Additional milestone payments to Galapagos could amount to $1 billion.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.